Researchers at MIT and Stanford University have developed a new way to stimulate the immune system to attack tumor cells, using a strategy that could make cancer immunotherapy work for many more ...

When the immune system overreacts and starts attacking the body, the only option may be to shut the entire system down and risk developing infections or cancer. Immune cells that are designed to ...

New findings reveal how cancer manipulates immune pathways and highlight therapeutic strategies to unleash T-cells against even the most resistant tumors. Study: Cancer cells impair monocyte-mediated ...

SGLT2 inhibitors combat inflammation and slow kidney disease by elevating S-adenosylmethionine (SAM) levels, which suppress inflammatory gene activity through epigenetic modification. The benefits of ...

Use of SGLT2 inhibitors before emergency surgery was not associated with an increased risk for postoperative diabetic ketoacidosis. The FDA previously issued guidance on withholding SGLT2 inhibitors ...

BOSTON -- Sodium-glucose cotransporter-2 (SGLT2) inhibitors were linked to long-term reductions in mortality risk among patients with pulmonary arterial hypertension (PAH), according to an ...

MIT and Harvard scientists have designed an advanced type of immune cell called a CAR-NK cell that can destroy cancer while avoiding attack from the body’s own immune defenses. This innovation could ...

CAR-T was developed to wipe out hard-to-treat blood cancers. But the cells that go bad in leukemias and lymphomas — immune ...